Operations take hit in AstraZeneca cuts; Daiichi Sankyo earnings cut by Ranbaxy issues;

> About 1,300 operations and supply chain positions will be lost as part of AstraZeneca's ($AZN) 7,300 job cuts aimed at saving $1.6 billion by the end of 2014. AZ release | Piece  

> An executive with Japan's Daiichi Sankyo, whose earnings were undercut by issues related to a consent decree signed by its majority-owned subsidiary Ranbaxy Laboratories, said the company will do its "best to transfer to Ranbaxy all the necessary domestic know-how in manufacturing technology and quality assurance." Story    

> After a FDA pre-approval inspection, contract manufacturing organization Pharmaceutics International has started construction of a 24,000-sq.-ft. cGMP aseptic fill/finish manufacturing facility at its Hunt Valley, MD, campus. Release

> Vitaflo USA is recalling Batch Number 12832 of its Renastart 14.11 oz (400g) cans, manufactured by a contract manufacturer in the U.K., because some of the medical food shipped throughout the U.S. from Dec. 29  through Jan. 26 was incorrectly labeled. Recall

> Aptar Pharma, the Crystal Lake, IL, maker of nasal and pulmonary drug delivery devices, has opened a new manufacturing site in Mumbai, India, its second in Asia after Suzhou in China. Aptar release 

> Saudi Arabia-based Arabio, which last year opened a 10,000-sq.-meter manufacturing facility in Makkah, has appointed Alphamed as its sales and distribution partner in the United Arab Emirates (UAE). Story 

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.